We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-26.27%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$2.23B
AUM Growth
-$1.32B
Cap. Flow
-$302M
Cap. Flow %
-13.54%
Top 10 Hldgs %
55.24%
Holding
55
New
2
Increased
1
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
TWST icon
Twist Bioscience
TWST
+$11.6M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$10.5M
3
TSVT
2seventy bio
TSVT
+$10.4M

Top Sells

Rank Stock Value
1
CDXS icon
Codexis
CDXS
+$83.5M
2
EXAS
Exact Sciences
EXAS
+$51.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$42.1M
4
ALLO icon
Allogene Therapeutics
ALLO
+$39.5M
5
ALEC icon
Alector
ALEC
+$34.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
26
Guardant Health
GH
$21.3B
$27.8M 1.25%
420,000
-370,000
-47% -$25.3M
DMTK
27
DELISTED
DermTech, Inc. Common Stock
DMTK
$25.6M 1.15%
1,745,000
– –
DNA icon
28
Ginkgo Bioworks
DNA
$584M
$16.9M 0.76%
105,070
-3,152
-3% -$614K
WGS icon
29
GeneDx Holdings
WGS
$2.01B
$15.3M 0.69%
151,515
– –
ADPT icon
30
Adaptive Biotechnologies
ADPT
$3.68B
$13.9M 0.62%
1,000,000
– –
GLUE icon
31
Monte Rosa Therapeutics
GLUE
$1.3B
$13.5M 0.6%
960,882
– –
SEER icon
32
Seer Inc
SEER
$123M
$12.2M 0.55%
800,000
– –
TSVT
33
DELISTED
2seventy bio
TSVT
$10.5M 0.47%
+614,754
New +$10.4M
EXAI
34
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$10.3M 0.46%
713,900
– –
GBIO
35
DELISTED
Generation Bio
GBIO
$9.72M 0.44%
132,428
– –
SNCE
36
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$9.63M 0.43%
90,000
– –
OMIC
37
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$9.11M 0.41%
48,096
– –
MRTX
38
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.43M 0.38%
+102,500
New +$10.5M
FDMT icon
39
4D Molecular Therapeutics
FDMT
$527M
$8.4M 0.38%
555,455
– –
DNTH icon
40
Dianthus Therapeutics
DNTH
$5.8B
$8.04M 0.36%
173,342
-70,507
-29% -$3.85M
ZLAB icon
41
Zai Lab
ZLAB
$2.05B
$6.6M 0.3%
150,000
– –
CDXS icon
42
Codexis
CDXS
$156M
$6.19M 0.28%
300,000
-4,030,000
-93% -$83.5M
KRON
43
DELISTED
Kronos Bio
KRON
$4.22M 0.19%
583,436
– –
RXRX icon
44
Recursion Pharmaceuticals
RXRX
$1.69B
$3.92M 0.18%
548,156
– –
ORIC icon
45
Oric Pharmaceuticals
ORIC
$1.1B
$3.21M 0.14%
601,515
– –
DBTX
46
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$1M 0.05%
330,000
-840,048
-72% -$3.22M
LIAN
47
DELISTED
LianBio American Depositary Shares
LIAN
$766K 0.03%
206,415
– –
ALEC icon
48
Alector
ALEC
$168M
– –
-1,650,000
Closed -$34.1M
ALLO icon
49
Allogene Therapeutics
ALLO
$635M
– –
-2,650,000
Closed -$39.5M
CRSP icon
50
CRISPR Therapeutics
CRSP
$4.88B
– –
-266,430
Closed -$20.2M
1
2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Casdin Capital held 55 positions worth $2.23B, down 37% from $3.55B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Casdin Capital withdrew a net $302M in Q1 2022, closing 8 positions and reducing 7 holdings. Its most notable exit was Allogene Therapeutics, an estimated $39.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier.

Against the trend, Casdin Capital opened a new position in Mirati Therapeutics, Inc. Common Stock worth $8.43M.

  • Casdin Capital's largest Q1 2022 buy was Mirati Therapeutics, Inc. Common Stock: 102,500 shares worth $8.43M.
  • Casdin Capital added most to Twist Bioscience in Q1 2022, an estimated $11.6M increase.
  • Casdin Capital's biggest Q1 2022 reduction was Codexis, cutting an estimated $83.5M.
  • Casdin Capital fully exited Allogene Therapeutics in Q1 2022, selling an estimated $39.5M.
  • Casdin Capital's ten largest holdings make up 55% of its $2.23B portfolio in Q1 2022.
  • Casdin Capital opened 2 new positions and closed 8 in Q1 2022.
  • Casdin Capital's portfolio value fell 37% quarter-over-quarter to $2.23B.

Based on Casdin Capital's 13F filing for Q1 2022, filed 16 May 2022.